Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

Ozanimod is a sphingosine 1-phosphate receptor modulator, which selectively binds to sphingosine 1-phosphate receptor subtypes 1 and 5 with high affinity. In the RADIANCE phase 2 study in participants with relapsing multiple sclerosis, ozanimod was associated with better efficacy than placebo on MRI...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Lancet neurology 2019-11, Vol.18 (11), p.1021-1033
Hauptverfasser:	Cohen, Jeffrey A, Comi, Giancarlo, Selmaj, Krzysztof W, Bar-Or, Amit, Arnold, Douglas L, Steinman, Lawrence, Hartung, Hans-Peter, Montalban, Xavier, Kubala Havrdová, Eva, Cree, Bruce A C, Sheffield, James K, Minton, Neil, Raghupathi, Kartik, Huang, Vivian, Kappos, Ludwig
Format:	Artikel
Sprache:	eng
Schlagworte:	Chicken pox Clinical outcomes Clinical trials Edema Gadolinium Heart rate Interferon Lymphocytes Magnetic resonance imaging Multiple sclerosis Safety Sphingosine 1-phosphate Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!